Trade Mark Journal No.2026/007 13 February 2026

UK00004327820 21 January 2026 (1)

MOSEIC

International priority date claimed: 17 November 2025 (United States of America) (99500515)

Class 1: Bioavailability enhancing molecular complex as an intermediate product in the manufacture of pharmaceuticals for the treatment of migraines, neurological disorders and central nervous system disorders.

Axsome Therapeutics, Inc.

Representative: Keltie LLP